677 related articles for article (PubMed ID: 28809995)
1. Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study.
Strober B; Bagel J; Lebwohl M; Stein Gold L; Jackson JM; Chen R; Goncalves J; Levi E; Callis Duffin K
J Drugs Dermatol; 2017 Aug; 16(8):801-808. PubMed ID: 28809995
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.
Stein Gold L; Bagel J; Lebwohl M; Jackson JM; Chen R; Goncalves J; Levi E; Duffin KC
J Drugs Dermatol; 2018 Feb; 17(2):221-228. PubMed ID: 29462231
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
Reich K; Gooderham M; Green L; Bewley A; Zhang Z; Khanskaya I; Day RM; Goncalves J; Shah K; Piguet V; Soung J
J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):507-517. PubMed ID: 27768242
[TBL] [Abstract][Full Text] [Related]
4. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
Ohtsuki M; Okubo Y; Komine M; Imafuku S; Day RM; Chen P; Petric R; Maroli A; Nemoto O
J Dermatol; 2017 Aug; 44(8):873-884. PubMed ID: 28391657
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).
Paul C; Cather J; Gooderham M; Poulin Y; Mrowietz U; Ferrandiz C; Crowley J; Hu C; Stevens RM; Shah K; Day RM; Girolomoni G; Gottlieb AB
Br J Dermatol; 2015 Dec; 173(6):1387-99. PubMed ID: 26357944
[TBL] [Abstract][Full Text] [Related]
6. Apremilast mechanism of efficacy in systemic-naive patients with moderate plaque psoriasis: Pharmacodynamic results from the UNVEIL study.
Strober B; Alikhan A; Lockshin B; Shi R; Cirulli J; Schafer P
J Dermatol Sci; 2019 Dec; 96(3):126-133. PubMed ID: 31787506
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study.
Papp KA; Kaufmann R; Thaçi D; Hu C; Sutherland D; Rohane P
J Eur Acad Dermatol Venereol; 2013 Mar; 27(3):e376-83. PubMed ID: 23030767
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
Reich K; Gooderham M; Bewley A; Green L; Soung J; Petric R; Marcsisin J; Cirulli J; Chen R; Piguet V
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):397-402. PubMed ID: 29220542
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study.
Van Voorhees AS; Stein Gold L; Lebwohl M; Strober B; Lynde C; Tyring S; Cauthen A; Sofen H; Zhang Z; Paris M; Wang Y
J Am Acad Dermatol; 2020 Jul; 83(1):96-103. PubMed ID: 32032692
[TBL] [Abstract][Full Text] [Related]
10. Open-Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed Therapy With Apremilast.
Bagel J; Samad AS; Stolshek BS; Aras GA; Chung JB; Kricorian G; Kircik LH
J Drugs Dermatol; 2018 Oct; 17(10):1078-1082. PubMed ID: 30365588
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial.
Stein Gold L; Papp K; Pariser D; Green L; Bhatia N; Sofen H; Albrecht L; Gooderham M; Chen M; Paris M; Wang Y; Callis Duffin K
J Am Acad Dermatol; 2022 Jan; 86(1):77-85. PubMed ID: 34343599
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.
Papp K; Cather JC; Rosoph L; Sofen H; Langley RG; Matheson RT; Hu C; Day RM
Lancet; 2012 Aug; 380(9843):738-46. PubMed ID: 22748702
[TBL] [Abstract][Full Text] [Related]
13. Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials.
Thaçi D; Kimball A; Foley P; Poulin Y; Levi E; Chen R; Feldman SR
J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):498-506. PubMed ID: 27538241
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trial.
Fiorillo L; Becker E; de Lucas R; Belloni-Fortina A; Armesto S; Elewski B; Maes P; Oberoi RK; Paris M; Zhang W; Zhang Z; Arkin L
J Am Acad Dermatol; 2024 Jun; 90(6):1232-1239. PubMed ID: 38266683
[TBL] [Abstract][Full Text] [Related]
15. Real-World Clinical Experience With Apremilast in a Large US Retrospective Cohort Study of Patients With Moderate to Severe Plaque Psoriasis.
Armstrong A; Levi E
J Drugs Dermatol; 2017 Dec; 16(12):1240-1245. PubMed ID: 29240859
[TBL] [Abstract][Full Text] [Related]
16. Use of Apremilast in Patients Who Are Dissatisfied With Stable Maintenance Topical Therapy.
Aljaser M; Amar L; Kircik LH
J Drugs Dermatol; 2019 Apr; 18(4):336-340. PubMed ID: 31012561
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study.
Gottlieb AB; Matheson RT; Menter A; Leonardi CL; Day RM; Hu C; Schafer PH; Krueger JG
J Drugs Dermatol; 2013 Aug; 12(8):888-97. PubMed ID: 23986162
[TBL] [Abstract][Full Text] [Related]
18. Apremilast and Narrowband Ultraviolet-B Combination Therapy for Treating Moderate-to-Severe Plaque Psoriasis.
Bagel J; Nelson E; Keegan BR
J Drugs Dermatol; 2017 Oct; 16(10):957-962. PubMed ID: 29036248
[TBL] [Abstract][Full Text] [Related]
19. Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis.
Papadavid E; Rompoti N; Theodoropoulos K; Kokkalis G; Rigopoulos D
J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):1173-1179. PubMed ID: 29388335
[TBL] [Abstract][Full Text] [Related]
20. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.
Bissonnette R; Pariser DM; Wasel NR; Goncalves J; Day RM; Chen R; Sebastian M
J Am Acad Dermatol; 2016 Jul; 75(1):99-105. PubMed ID: 27021239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
